Our mission is to enable access to high quality, affordable,
specialty NGS testing, performed by any NGS laboratory as
clinical grade tests, closer to home, for all patients.
Chief Executive Officer Mr. Randy Pritchard is CEO of Pillar Biosciences. He has more than 24 years of healthcare experience as a diagnostics executive who has deep experience in corporate and commercial strategy, sales and marketing, and driving growth through innovation. He has held positions of increasing responsibilities, including SVP of US Diagnostics marketing, SVP & Lifecycle Leader at the divisions of POC Diagnostic & Core Reagents, and VP of Marketing at Centralized Diagnostics at Roche Diagnostics. He completed his undergraduate studies at Purdue University and his MBA at Indiana Wesleyan University.
Zhaohui Wang, Ph.D.
Co-founder and Chief Scientific Officer Dr. Zhaohui Wang co-founded Pillar Biosciences, and co-invented SLIMamp technology. Previously, she held positions of increasing responsibility at LabCorp (previously Genzyme Genetics) and IQuum (subsequently acquired by Roche Molecular Diagnostics). Dr. Wang received her Ph.D. in Cellular and Molecular Biology from the University of Massachusetts, Amherst.
Chief Financial Officer Rick Shea served as the Chief Financial Officer of Syndax Pharmaceuticals, Inc. from February 2017 to July 2020. Rick previously served as a member of the Syndax Pharmaceuticals board of directors from January 2014 to February 2017. From July 2007 through December 2016, he served as Senior Vice President and Chief Financial Officer of Momenta Pharmaceuticals Inc., a publicly traded biotechnology company, and was its Vice President and Chief Financial Officer since October 2003. Prior to joining Momenta, Rick served as Chief Operating Officer and Chief Financial Officer of Variagenics Inc., a publicly traded pharmacogenomics company, that was merged with Hyseq Pharmaceuticals Inc., and as Vice President, Finance of Genetics Institute, Inc., a publicly traded biotechnology company, which was acquired by Wyeth Pharmaceuticals, Inc., which was then acquired by Pfizer, Inc. Rick received an AB from Princeton University and an MBA from the Public Management Program at Boston University.
Chief Commercial Officer Mr. Dan Harma is the Chief Commercial Officer of Pillar Biosciences. He has more than 30 years of experience in the medical device industry, notably in in-vitro diagnostics, molecular diagnostics, and hematology markets. Prior to joining Pillar Biosciences, he served as Chief Commercial Officer at NeuMoDxTM where he led the commercial team and assisted in transitioning the business from research and development stage to full commercialization. Previously, he held multiple roles at Abbott Laboratories, Inc., in both the Diagnostics and Molecular divisions. His positions included oversight of product marketing, sales leadership, and commercial development. Mr. Harma received his MBA from Loyola University and his BBA in Marketing from the University of Wisconsin-Whitewater.
Vice President of Operations Mr. Mike Crowell is VP of Operations for Pillar Biosciences. He has more than 25 years of healthcare experience with 20 plus years leading operations for molecular diagnostic companies. He has developed deep experience helping regulated life sciences organizations achieve sustained competitive advantage and growth through enhanced customer experience, operational efficiency, organizational agility, and continuous process improvement. He has held positions of increasing responsibilities, including Sr. Director of Operations, Supply Chain and OpEx with Illumina Inc., and Sr. Director Global Supply Chain with Tethys Bioscience and Monogram Biosciences (LabCorp) respectively. Mr. Crowell received a master’s degree from National University of Singapore in International Business as well as an MBA from UCLA Anderson School of Management.
Qiang Wang, PhD
General Manager, China Dr. Qiang Wang is General Manager for Zhengu Biotech (Pillar China). Dr. Wang has more than 15 years of leadership experience in the biotech and pharmaceutical industries. He has held positions as General Manager of Shanghai Fosun Pharmaceutical Co. and Deputy General Manager of Shanghai Sea rainbow medicine e-commerce Co., Ltd. Dr. Wang received his Ph.D. in Health Economics from Fudan University and an MBA from Shanghai Jiaotong University.
General Counsel Ms. Christa Adkins is General Counsel at Pillar Biosciences. She has more than 20 years of experience as internal counsel to multi-national corporations and early-stage companies. Prior to joining Pillar Biosciences, she served as General Counsel, Corporate Secretary, and Member of the Equity Incentive Plan Committee at Vibenomics, Inc. Previously, she spent more than 10 years at Roche Diagnostic Corporation, as Commercial Lawyer and Director of Ethics and Compliance. She also has extensive nonprofit board leadership experience and is currently the Chair of the Board of Trustees for the Nature Conservancy of Indiana, Trustee for the Indianapolis Zoological Society, and Trustee for the Orchard School. Ms. Adkins holds a JD from Indiana University Robert H. McKinney School of Law and a BS in Economics from Purdue University.